Enclomiphene vs Raloxifene
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Enclomiphene and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Raloxifene
Weight 405.96 Da 473.58 Da
Half-life ~10 hours ~28 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Benzothiophene-derived selective estrogen receptor modulator
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Raloxifene
01 Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
02 No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
03 Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
04 Lower overall thromboembolic risk compared to tamoxifen
05 Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
06 Simple once-daily oral dosing with a manageable 28-hour half-life
07 FDA-approved with decades of clinical safety data in postmenopausal women
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Raloxifene
Hot flashes and increased sweating
Leg cramps and muscle spasms
Joint pain or stiffness
Peripheral edema (mild swelling in extremities)
Flu-like symptoms during initial weeks
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
History of deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, or other venous thromboembolic events
Active or past history of stroke or transient ischemic attack
Known hypersensitivity to raloxifene hydrochloride or any excipients
Pregnancy or planned pregnancy (category X -- contraindicated)
Prolonged immobilization (e.g., post-surgical recovery, extended bed rest) due to elevated DVT risk
Severe hepatic impairment
Research Evidence
Enclomiphene Raloxifene
Status Well Studied FDA Approved
References 5 studies 4 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.